# An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

> **NCT00728195** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 498 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** JNJ-37822681
- **DRUG:** JNJ-37822681
- **DRUG:** JNJ-37822681
- **DRUG:** Olanzapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00728195
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 498 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00728195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00728195, "An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00728195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*